Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

Miller, Richard L.; Gerster, John F.; Owens, Mary; Slade, Herbert B.; Tomai, Mark A.

doi:10.1016/s0192-0561(98)00068-x

Cited by 386 publications

(339 citation statements)

References 34 publications

Supporting

Mentioning

308

Contrasting

Unclassified

Order By: Relevance

“…IQ has also been reported to be suitable for the treatment of molluscum contagiosum, basal cell carcinoma, and Bowen's disease (13)(14)(15). Although the exact mechanism of action of IQ is unknown, it is believed that imiquimod modulates immune responses by activating dendritic cells, macrophage, or other cells via Toll-like receptor 7 (TLR7), releasing IFN-α/β and proinflammatory cytokines (16)(17)(18). In addition, it has been reported that there are adverse side effects resulting from the treatments.…”

mentioning

confidence: 99%

Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons

Kim

Park

Kim

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

Despite its clinical importance, the mechanisms that mediate or generate itch are poorly defined. The identification of pruritic compounds offers insight into understanding the molecular and cellular basis of itch. Imiquimod (IQ) is an agonist of Toll-like receptor 7 (TLR7) used to treat various infectious skin diseases such as genital warts, keratosis, and basal cell carcinoma. Itch is reportedly one of the major side effects developed during IQ treatments. We found that IQ acts as a potent itch-evoking compound (pruritogen) in mice via direct excitation of sensory neurons. Combined studies of scratching behavior, patch-clamp recording, and Ca 2+ response revealed the existence of a unique intracellular mechanism, which is independent of TLR7 as well as different from the mechanisms exploited by other well-characterized pruritogens. Nevertheless, as for other pruritogens, IQ requires the presence of transient receptor potential vanilloid 1 (TRPV1)-expressing neurons for itchassociated responses. Our data provide evidence supporting the hypothesis that there is a specific subset of TRPV1-expressing neurons that is equipped with diverse intracellular mechanisms that respond to histamine, chloroquine, and IQ.

show abstract

mentioning

confidence: 99%

Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons

Kim

Park

Kim

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

show abstract

“…Это приводит к уменьшению боро-давок, вызванному иммунным ответом, и к сниже-нию количества ДНК ВПЧ [20,21].…”

Section: крем имихимод (кераворт)unclassified

“…Исходя из данных ранее проведенных исследо-ваний, полное разрешение исходных бородавок у 56% пациентов и значительное уменьшение площа-ди их поверхности еще у большего количества паци-ентов хорошо сравнимы с результатами имеющейся более агрессивной и раздражающей терапии аноге-нитальных бородавок [20,21]. По данным литерату-ры [25][26][27][28], отмечается полное разрешение всех подвергнутых воздействию бородавок у 32-80% па-циентов, получавших подофиллин, у 70-80% паци-ентов, у которых использовалась криохирургия, и практически у 80% пациентов, получавших дихлор-уксусную и трихлоруксусную кислоту.…”

Section: крем имихимод (кераворт)unclassified

Human papillomavirus: local treatment of anogenital lesions

Khryanin¹,

Reshetnikov²,

Lobzev³

et al. 2016

Klin. dermatol. venerol.

View full text Add to dashboard Cite

“…It is important to find a balance between what is an effective treatment dosage and the release duration. Miller et al [48] showed the effective concentration of imiquimod in human cells to initiate a response was between 1 and 5 μg/mL. Fibers could be customized to maintain this effective concentration with an adequate release rate.…”

Section: Drug Release Profilementioning

confidence: 99%

Biodegradable Nanofiber for Delivery of Immunomodulating Agent in the Treatment of Basal Cell Carcinoma

Garrett

Niiyama

Kotsuchibashi

et al. 2015

Fibers

View full text Add to dashboard Cite

Abstract:In this paper we investigate a potential new treatment option for basal cell carcinoma using electrospun polymer nanofibers. Poly(ε-caprolactone) fibers incorporated with the anti-cancer drug imiquimod were successfully produced for the first time. These fibers were characterized and their diffusion release profile tested in vitro. A range of different electrospinning parameters were investigated in order to determine the most effective approach in optimizing the fibers for future in vivo testing. Characterization showed stable and homogeneous distribution of imiquimod. Although the drug was released faster than what would be needed to replicate the current treatment model, this system would ideally allow for a treatment option which reduces side effects and is more convenient for the patient than the current topical treatment.

show abstract

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

Cited by 386 publications

References 34 publications

Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons

Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons

Human papillomavirus: local treatment of anogenital lesions

Biodegradable Nanofiber for Delivery of Immunomodulating Agent in the Treatment of Basal Cell Carcinoma

Contact Info

Product

Resources

About